Pomerantz Law Firm Launches Investigation Into Hims & Hers Health, Inc. Following Allegations of Fraud
In a significant development for investors of Hims & Hers Health, Inc. (NYSE: HIMS), the Pomerantz Law Firm has announced an investigation into potential securities fraud and regulatory violations concerning the company. This investigation comes as the firm seeks to protect the interests of investors who may have suffered due to the firm's allegedly unlawful business practices.
On July 29, 2026, the U.S. Federal Trade Commission (FTC) filed a lawsuit against Hims, accusing the company of sharing sensitive medical information of its customers with third-party advertisers. The lawsuit alleges that these actions represented deceptive and illegal privacy practices, particularly in relation to the handling of patient health information, which was reportedly shared with major platforms like Meta, Snap, and Facebook.
Following the FTC's lawsuit, Hims experienced a substantial drop in its stock price, falling by $4.32 per share (approximately 14.73%), closing at $25.00 on the day the news broke. Investors reacted sharply to the implications of the FTC's accusations, highlighting the serious financial repercussions of such allegations.
Adding to the scrutiny, on August 21, 2026, reports from Bloomberg indicated that Hims had received notifications from Visa Inc. concerning excessive customer complaints linked to its weight-loss subscription service. Internal documents revealed that Hims has been enrolled in Visa's Acquirer Monitoring Program after a spike in customer disputes regarding credit card charges. These complaints not only raise questions about Hims' customer service practices and billing policies but also suggest a potentially troubling pattern of behavior, further damaging investor confidence.
After the revelation of the complaints from Visa, Hims' stock experienced another blow, plummeting $2.70 per share (around 7.99%), closing at $31.08 on August 24, 2026. This further decline emphasizes the mounting challenges the company faces, both from a legal standpoint and in terms of market performance.
Pomerantz LLP, a well-recognized firm in the realms of corporate and securities litigation, has a long-standing history of battling for the rights of investors. Since its establishment by the late Abraham L. Pomerantz, the firm has earned a reputation for its commitment to seeking justice for victims of securities fraud and corporate misconduct. With offices in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz continues to be a formidable presence in legal advocacy.
As the investigation unfolds, creditors and investors of Hims & Hers Health, Inc. are encouraged to reach out to Pomerantz for more information and to discuss their legal options. Those affected can contact Danielle Peyton at the law firm's dedicated line for inquiries regarding this case. Potential class members are also advised to inform themselves about the ongoing investigation and consider the implications of these serious allegations.
In the coming months, as the situation develops, the impact on Hims & Hers Health, Inc. and its investors will come into sharper focus. Stakeholders will remain vigilant as legal proceedings progress, which may unveil more extensive insights into the corporate practices at Hims and lead to further consequences for the firm and its executives.
On July 29, 2026, the U.S. Federal Trade Commission (FTC) filed a lawsuit against Hims, accusing the company of sharing sensitive medical information of its customers with third-party advertisers. The lawsuit alleges that these actions represented deceptive and illegal privacy practices, particularly in relation to the handling of patient health information, which was reportedly shared with major platforms like Meta, Snap, and Facebook.
Following the FTC's lawsuit, Hims experienced a substantial drop in its stock price, falling by $4.32 per share (approximately 14.73%), closing at $25.00 on the day the news broke. Investors reacted sharply to the implications of the FTC's accusations, highlighting the serious financial repercussions of such allegations.
Adding to the scrutiny, on August 21, 2026, reports from Bloomberg indicated that Hims had received notifications from Visa Inc. concerning excessive customer complaints linked to its weight-loss subscription service. Internal documents revealed that Hims has been enrolled in Visa's Acquirer Monitoring Program after a spike in customer disputes regarding credit card charges. These complaints not only raise questions about Hims' customer service practices and billing policies but also suggest a potentially troubling pattern of behavior, further damaging investor confidence.
After the revelation of the complaints from Visa, Hims' stock experienced another blow, plummeting $2.70 per share (around 7.99%), closing at $31.08 on August 24, 2026. This further decline emphasizes the mounting challenges the company faces, both from a legal standpoint and in terms of market performance.
Pomerantz LLP, a well-recognized firm in the realms of corporate and securities litigation, has a long-standing history of battling for the rights of investors. Since its establishment by the late Abraham L. Pomerantz, the firm has earned a reputation for its commitment to seeking justice for victims of securities fraud and corporate misconduct. With offices in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz continues to be a formidable presence in legal advocacy.
As the investigation unfolds, creditors and investors of Hims & Hers Health, Inc. are encouraged to reach out to Pomerantz for more information and to discuss their legal options. Those affected can contact Danielle Peyton at the law firm's dedicated line for inquiries regarding this case. Potential class members are also advised to inform themselves about the ongoing investigation and consider the implications of these serious allegations.
In the coming months, as the situation develops, the impact on Hims & Hers Health, Inc. and its investors will come into sharper focus. Stakeholders will remain vigilant as legal proceedings progress, which may unveil more extensive insights into the corporate practices at Hims and lead to further consequences for the firm and its executives.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.